Satoru Sagae1, Bradley J Monk, Eric Pujade-Lauraine, David K Gaffney, Kailash Narayan, Sang Young Ryu, Mary McCormack, Marie Plante, Antonio Casado, Alexander Reuss, Adriana Chávez-Blanco, Henry Kitchener, Byung-Ho Nam, Anuja Jhingran, Sarah Temkin, Linda Mileshkin, Els Berns, Suzy Scholl, Corinne Doll, Nadeem R Abu-Rustum, Fabrice Lecuru, William Small. 1. *Department of Gynecologic Oncology, Sapporo West Kojinkai Clinic, Sapporo, Japan; †University of Arizona Cancer Center-Phoenix, Creighton University School of Medicine at St Joseph's Hospital and Medical Center, Phoenix, AZ; ‡Hôtel-Dieu, AP-HP, Université Paris Descartes, Paris, France; §Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah Health Care, Salt Lake City, UT; ∥Division of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; ¶Department of Surgery, Chonnam National University Medical School, Gwangju, South Korea; #Department of Oncology, University College Hospital London, London, United Kingdom; **Division of Gynecologic Oncology, Centre Hospitalier Universitaire de Québec, Quebec, Quebec, Canada; ††Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain; ‡‡Coordinating Center for Clinical Trials of the Phipps-University of Marburg, Marburg, Germany; §§GICOM Grupo Mexicano de Investigación en Cáncer de Ovario y Tumores Ginecológicos, A.C. México City, México; ∥∥Institute of Cancer Sciences, University of Manchester, St Mary's Hospital, Manchester, United Kingdom; ¶¶Biotechnology Research Division, National Fisheries Research and Development Institute, Busan, South Korea; ##Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; ***Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD; †††Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; ‡‡‡Médecin - Spécialiste en Oncologie, Institut Curie, Paris, France; §§§Division of Radiation Oncology, Department Oncology, University of Calgary, Calgary, Alberta, Canada; ∥∥∥Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; ¶¶¶Chir
Abstract
OBJECTIVE: Cervical cancer is responsible for more than a quarter of a million deaths globally each year, mostly in developing countries, making therapeutic advances in all health care settings a top priority. The Gynecologic Cancer InterGroup (GCIG) is a worldwide collaboration of leading national research groups that develops and promotes multinational trials in gynecologic cancer. In recognition of the pressing need for action, the GCIG convened an international meeting with expert representation from the GCIG groups and selected large sites in low- and middle-income countries. METHODS: The focus was to develop a consensus on several concepts for future clinical trials, which would be developed and promoted by the GCIG and launched with major international participation. The first half of the meeting was devoted to a resume of the current state of the knowledge and identifying the gaps in need of new evidence, validating control arms for present and future clinical trials and identifying national and international barriers for studies of cervix cancers. The second half of the meeting was concerned with achieving consensus on a path forward. RESULTS AND CONCLUSIONS: There were 5 principal outcomes as follows: first, a proposal to expand fertility-preserving options with neoadjuvant chemotherapy; second, validation of the assessment of sentinel lymph nodes using minimally invasive surgery with an emphasis on identification and management of low-volume metastasis, such as isolated tumor cells and micrometastasis; third, evaluation of hypofractionation for palliative and curative radiation under the umbrella of the GCIG Cervix Cancer Research Network; fourth, adding to the advances in antiangiogenesis therapy in the setting of metastatic disease; and fifth, developing a maintenance study among women at high risk of relapse. The latter 2 systemic interventions could study PI3K (phosphatidylinositol-3-kinase) inhibitors, immunotherapy, anti-human papillomavirus approaches, or novel antiangiogenic agents/combinations.
OBJECTIVE:Cervical cancer is responsible for more than a quarter of a million deaths globally each year, mostly in developing countries, making therapeutic advances in all health care settings a top priority. The Gynecologic Cancer InterGroup (GCIG) is a worldwide collaboration of leading national research groups that develops and promotes multinational trials in gynecologic cancer. In recognition of the pressing need for action, the GCIG convened an international meeting with expert representation from the GCIG groups and selected large sites in low- and middle-income countries. METHODS: The focus was to develop a consensus on several concepts for future clinical trials, which would be developed and promoted by the GCIG and launched with major international participation. The first half of the meeting was devoted to a resume of the current state of the knowledge and identifying the gaps in need of new evidence, validating control arms for present and future clinical trials and identifying national and international barriers for studies of cervix cancers. The second half of the meeting was concerned with achieving consensus on a path forward. RESULTS AND CONCLUSIONS: There were 5 principal outcomes as follows: first, a proposal to expand fertility-preserving options with neoadjuvant chemotherapy; second, validation of the assessment of sentinel lymph nodes using minimally invasive surgery with an emphasis on identification and management of low-volume metastasis, such as isolated tumor cells and micrometastasis; third, evaluation of hypofractionation for palliative and curative radiation under the umbrella of the GCIGCervix Cancer Research Network; fourth, adding to the advances in antiangiogenesis therapy in the setting of metastatic disease; and fifth, developing a maintenance study among women at high risk of relapse. The latter 2 systemic interventions could study PI3K (phosphatidylinositol-3-kinase) inhibitors, immunotherapy, anti-human papillomavirus approaches, or novel antiangiogenic agents/combinations.
Authors: Kjetil Søreide; Derek Alderson; Anders Bergenfelz; John Beynon; Saxon Connor; Dan L Deckelbaum; Cornelis H Dejong; Jonathan J Earnshaw; Patrick Kyamanywa; Rodrigo O Perez; Yoshiharu Sakai; Desmond C Winter Journal: Lancet Date: 2013-09-28 Impact factor: 79.321
Authors: Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter Journal: J Natl Cancer Inst Date: 2013-03-06 Impact factor: 13.506
Authors: Akinyemi I Ojesina; Lee Lichtenstein; Samuel S Freeman; Chandra Sekhar Pedamallu; Ivan Imaz-Rosshandler; Trevor J Pugh; Andrew D Cherniack; Lauren Ambrogio; Kristian Cibulskis; Bjørn Bertelsen; Sandra Romero-Cordoba; Victor Treviño; Karla Vazquez-Santillan; Alberto Salido Guadarrama; Alexi A Wright; Mara W Rosenberg; Fujiko Duke; Bethany Kaplan; Rui Wang; Elizabeth Nickerson; Heather M Walline; Michael S Lawrence; Chip Stewart; Scott L Carter; Aaron McKenna; Iram P Rodriguez-Sanchez; Magali Espinosa-Castilla; Kathrine Woie; Line Bjorge; Elisabeth Wik; Mari K Halle; Erling A Hoivik; Camilla Krakstad; Nayeli Belem Gabiño; Gabriela Sofia Gómez-Macías; Lezmes D Valdez-Chapa; María Lourdes Garza-Rodríguez; German Maytorena; Jorge Vazquez; Carlos Rodea; Adrian Cravioto; Maria L Cortes; Heidi Greulich; Christopher P Crum; Donna S Neuberg; Alfredo Hidalgo-Miranda; Claudia Rangel Escareno; Lars A Akslen; Thomas E Carey; Olav K Vintermyr; Stacey B Gabriel; Hugo A Barrera-Saldaña; Jorge Melendez-Zajgla; Gad Getz; Helga B Salvesen; Matthew Meyerson Journal: Nature Date: 2013-12-25 Impact factor: 49.962
Authors: Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li Journal: Science Date: 2014-05-08 Impact factor: 47.728
Authors: Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: John B McIntyre; Jackson S Wu; Peter S Craighead; Tien Phan; Martin Köbel; Susan P Lees-Miller; Prafull Ghatage; Anthony M Magliocco; Corinne M Doll Journal: Gynecol Oncol Date: 2012-12-22 Impact factor: 5.482
Authors: Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245
Authors: Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch Journal: Cancer Date: 2013-08-23 Impact factor: 6.860
Authors: Filip Janku; Jennifer J Wheler; Aung Naing; Vanda M Stepanek; Gerald S Falchook; Siqing Fu; Ignacio Garrido-Laguna; Apostolia M Tsimberidou; Sarina A Piha-Paul; Stacy L Moulder; Jack J Lee; Rajyalakshmi Luthra; David S Hong; Razelle Kurzrock Journal: Oncotarget Date: 2012-12
Authors: Jill H Tseng; Alessia Aloisi; Yukio Sonoda; Ginger J Gardner; Oliver Zivanovic; Nadeem R Abu-Rustum; Mario M Leitao Journal: Int J Gynecol Cancer Date: 2018-09 Impact factor: 3.437